Volume 3, Issue 12, December 2025 ISSN (E): 2938-3765

ANTIMICROBIAL RESISTANCE AND OPTIMIZATION OF ANTIMICROBIAL THERAPY

Kalandarova Matlyuba Xodjiakbarovna
Assistant of the Department of Traditional Medicine and Pharmacology Fergana Medical Institute of Public Health

Abstract
Antimicrobial resistance represents one of the most formidable challenges to contemporary healthcare systems worldwide. This investigation examines the molecular mechanisms underlying resistance development, identifies critical gaps in current prescribing practices, and evaluates evidence-based strategies for optimizing antimicrobial therapy. Through analysis of international surveillance data, clinical guidelines, and pharmacodynamic principles, this study demonstrates that structured antimicrobial stewardship programs combined with precision-guided therapy can substantially mitigate resistance propagation. The findings underscore the urgent need for integrated approaches encompassing diagnostic innovation, prescriber education, and policy reform to preserve antimicrobial efficacy for future generations.

Keywords: Resistance, betalactamase, carbapenemase, staphylococcus, pharmacokinetics, deescalation, concentration, empiricism, combination, multiresistance, transfer, antibiogram, nosocomial, susceptibility.

Introduction

The discovery of penicillin fundamentally transformed medicine, yet less than a century later, antimicrobial resistance threatens to render many life-saving interventions obsolete. The World Health Organization has identified antimicrobial resistance as a top ten global public health threat, with resistant infections causing an estimated 1.27 million deaths annually. Projections suggest that without decisive intervention, drug-resistant infections could claim 10 million lives yearly by 2050, surpassing cancer mortality. The economic burden extends beyond direct healthcare costs to encompass productivity losses, prolonged hospitalizations, and the necessity for more expensive second-line therapies. The acceleration of resistance development has outpaced new antibiotic discovery, creating a narrowing therapeutic window for treating serious infections. This critical imbalance necessitates a fundamental shift in how antimicrobials are selected, dosed, and monitored in clinical practice. Optimizing antimicrobial therapy through evidence-based stewardship programs represents not merely a quality improvement initiative but an existential imperative for maintaining effective treatment options.

Literature Review

Global surveillance networks have documented alarming trends in resistance patterns across diverse healthcare settings. The European Centre for Disease Prevention and Control reports that carbapenem-resistant Enterobacteriaceae now affect significant proportions of intensive care units

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

throughout Europe, with some regions experiencing resistance rates exceeding forty percent in Klebsiella pneumoniae isolates. The Centers for Disease Control and Prevention classifies several resistant organisms as urgent threats, including carbapenem-resistant Acinetobacter and drug-resistant Neisseria gonorrhoeae, based on their clinical impact and limited therapeutic alternatives.

Recent meta-analyses examining antimicrobial stewardship interventions demonstrate meaningful reductions in inappropriate prescribing when programs incorporate prospective audit with feedback, formulary restrictions, and prescriber education. A systematic review published in Clinical Infectious Diseases analyzed seventy-three studies and found that comprehensive stewardship programs reduced broad-spectrum antimicrobial use by 34% without adversely affecting clinical outcomes. These findings contradict earlier concerns that restrictive policies might compromise patient safety.

Pharmacokinetic-pharmacodynamic research has illuminated optimal dosing strategies for maximizing bacterial killing while minimizing resistance selection. Time-dependent antimicrobials such as beta-lactams achieve optimal efficacy when serum concentrations remain above the minimum inhibitory concentration for substantial portions of the dosing interval, suggesting that extended infusions may improve outcomes in critically ill patients. Concentration-dependent agents like fluoroquinolones and aminoglycosides require higher peak concentrations relative to minimum inhibitory concentrations, favoring less frequent administration of larger doses.

MAIN PART

Bacterial resistance to antimicrobials develops through several key mechanisms. Chromosomal mutations may alter drug targets and reduce binding affinity, as seen when penicillin-binding protein changes in Streptococcus pneumoniae diminish beta-lactam effectiveness. While such mutations spread vertically, a far greater risk arises from horizontal gene transfer, which rapidly disseminates resistance traits across diverse species. ESBL-mediated resistance in Enterobacteriaceae remains a major concern, as these enzymes hydrolyze extended-spectrum cephalosporins and often reside on plasmids transferable via conjugation. Globally predominant CTX-M variants, especially CTX-M-15, are associated with higher mortality, prolonged hospitalization, and increased costs. Carbapenem resistance represents an even more severe challenge. Carbapenemases-including KPC and metallo-beta-lactamases-can inactivate nearly all beta-lactams, leaving clinicians with limited and often toxic alternatives such as colistin. Methicillin-resistant Staphylococcus aureus arises from acquisition of the mecA gene, producing a modified target enzyme with low beta-lactam affinity. Community strains frequently carry additional virulence factors, illustrating how resistance can coincide with enhanced pathogenicity. Efflux pump overexpression in Pseudomonas aeruginosa and Acinetobacter baumannii provides broad multidrug resistance by expelling diverse antimicrobials. Biofilm formation further shields bacteria by restricting drug penetration and reducing metabolic activity.

Clinical practice errors play a major role in accelerating antimicrobial resistance. Inappropriate drug selection remains widespread, with nearly one-third of outpatient prescriptions deemed unnecessary—most commonly for viral respiratory infections. Using broad-spectrum agents when narrower options are adequate not only increases selective pressure but also exposes patients to avoidable adverse effects. Suboptimal dosing is another critical issue. Underdosing prevents achievement of pharmacodynamic targets, enabling survival of resistant subpopulations. This problem is magnified in critically ill patients whose altered physiology or extracorporeal therapies

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

reduce antimicrobial concentrations. Despite this, therapeutic drug monitoring for applicable agents remains insufficiently utilized. Premature discontinuation of therapy also contributes to resistance. Although evidence supports shorter courses for select infections, many clinicians either prolong treatment unnecessarily or stop too early based on fever resolution alone rather than objective markers of response—both of which can encourage resistant strains to persist. The agricultural sector significantly fuels resistance. Around seventy percent of medically important antimicrobials in the U.S. are used in food-producing animals, often for non-therapeutic purposes like growth promotion. This massive selection pressure generates resistant organisms that can reach humans through contaminated food or environmental pathways. Despite regulatory attempts, inconsistent enforcement allows this reservoir of resistance to remain a global threat.

Principles of antimicrobial therapy optimization focus on maximizing efficacy while minimizing resistance. Antimicrobial stewardship programs provide structured frameworks including leadership, accountability, expertise, facility-specific interventions, monitoring, reporting, and prescriber education. These programs reduce inappropriate use, lower Clostridioides difficile rates, and cut healthcare costs without compromising outcomes. De-escalation therapy starts with broad-spectrum empirical treatment in seriously ill patients, then narrows therapy based on culture and susceptibility results. Success depends on timely microbiology data and prescriber adherence, balancing early effective therapy with stewardship principles. Pharmacokinetic-pharmacodynamic optimization tailors dosing to achieve bacterial eradication. Time-dependent drugs require maintaining concentrations above minimum inhibitory levels for a sufficient portion of the dosing interval, while concentration-dependent agents benefit from high peak levels to maximize killing and reduce resistance. Antibiogram-guided therapy uses local susceptibility data to inform empirical choices, improving the likelihood of active therapy. Regular updates ensure relevance across facilities and infection types. Combination therapy is reserved for infections with limited options, to prevent resistance, or for synergistic effect in difficult cases. Routine combination therapy offers no advantage over appropriate monotherapy and may increase cost, toxicity, and resistance risk. Decisions should rely on infection specifics, causative organisms, susceptibility data, and patient factors.

Table: Prevalent Resistant Microorganisms and Recommended Antimicrobial Approaches

Resistant Organism	First-Line Therapy	Alternative Agents	Key Considerations
ESBL-producing Enterobacteriaceae	Carbapenem (meropenem, ertapenem)	Cefepime (if MIC ≤2), piperacillin-tazobactam (urinary tract only)	Avoid cephalosporins and aztreonam for serious infections; carbapenem resistance increasingly common
Carbapenem-resistant Enterobacteriaceae	Ceftazidime-avibactam, meropenem-vaborbactam	Polymyxins, tigecycline, aminoglycosides (combination therapy often required)	Obtain infectious diseases consultation; newer beta-lactam/beta-lactamase inhibitors show superior outcomes to polymyxins
Methicillin-resistant Staphylococcus aureus	Vancomycin, daptomycin	Linezolid, ceftaroline, tedizolid	Monitor vancomycin trough concentrations; daptomycin ineffective for pneumonia; linezolid causes myelosuppression with prolonged use
Vancomycin-resistant Enterococcus	Linezolid, daptomycin	Tigecycline, quinupristin-dalfopristin	Distinguish between E. faecalis and E. faecium; latter shows broader resistance; infectious diseases consultation recommended
Multidrug-resistant Pseudomonas aeruginosa	Ceftolozane-tazobactam, ceftazidime-avibactam	Polymyxins, aminoglycosides (combination therapy often required)	Test susceptibility to all beta-lactams individually; resistance patterns vary substantially; higher doses may be necessary
Multidrug-resistant Acinetobacter baumannii	Polymyxins, ampicillin-sulbactam	Tigecycline, minocycline (combination therapy recommended)	Limited therapeutic options; high mortality rates; prolonged infusion of beta-lactams when susceptible

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

The selection of antimicrobial therapy for resistant organisms requires integration of susceptibility data, infection site, patient-specific pharmacokinetic considerations, and local resistance patterns. Carbapenem-sparing strategies for ESBL producers have gained attention due to rising carbapenem resistance, though evidence supporting alternatives for serious infections remains limited. For carbapenem-resistant organisms, newer beta-lactam/beta-lactamase inhibitor combinations demonstrate superior outcomes compared to polymyxin-based regimens in observational studies and should be prioritized when susceptibility permits.

Vancomycin dosing for MRSA infections requires therapeutic drug monitoring to achieve area-under-the-curve to minimum inhibitory concentration ratios associated with optimal efficacy while minimizing nephrotoxicity risk. Vancomycin failures in MRSA bacteremia with isolates exhibiting minimum inhibitory concentrations of 2 micrograms per milliliter or higher have prompted increased use of alternative agents such as daptomycin, though emerging daptomycin resistance following vancomycin failure has been documented. The selection between vancomycin and alternative agents should consider infection severity, vancomycin minimum inhibitory concentration, renal function, and concurrent nephrotoxic exposures. Treatment of vancomycin-resistant Enterococcus infections presents particular challenges, as these organisms demonstrate intrinsic resistance to many antimicrobial classes. Distinguishing between Enterococcus faecalis and Enterococcus faecium becomes critical, as the latter species exhibits substantially broader resistance patterns and typically requires more aggressive therapy. Linezolid penetrates well into most tissues and demonstrates bacteriostatic activity against VRE, though prolonged courses risk significant hematologic toxicity requiring monitoring.

Results

Analysis of antimicrobial stewardship implementation across diverse healthcare settings reveals consistent patterns of improved prescribing practices and reduced resistance rates. Institutions with mature stewardship programs demonstrate twenty to thirty percent reductions in broad-spectrum antimicrobial use, particularly carbapenems and fluoroquinolones, which represent major contributors to resistance selection pressure. These reductions correlate with decreased incidence of healthcare-associated infections caused by resistant organisms, including MRSA and carbapenem-resistant Enterobacteriaceae, suggesting that antimicrobial stewardship interventions successfully interrupt resistance propagation cycles. Pharmacokinetic-pharmacodynamic optimization strategies show measurable improvements in clinical outcomes for critically ill patients with serious infections. Studies examining extended-infusion beta-lactam administration demonstrate enhanced target attainment rates, particularly in patients with augmented renal clearance who achieve inadequate concentrations with standard intermittent dosing. Clinical outcome data increasingly support extended infusions for severe infections, with meta-analyses suggesting mortality reductions compared to standard dosing regimens, though high-quality randomized controlled trials remain limited.

De-escalation strategies prove feasible in the majority of patients when supported by rapid diagnostic technologies and structured stewardship interventions. Research indicates that de-escalation occurs in approximately sixty to seventy percent of patients initiated on broad-spectrum empirical therapy when timely microbiology results and clinical reassessment protocols are implemented. Importantly,

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

de-escalation does not adversely affect mortality or treatment failure rates when performed appropriately, addressing earlier concerns about potentially compromising patient safety through therapy narrowing. The integration of rapid diagnostic technologies, including multiplex polymerase chain reaction panels and matrix-assisted laser desorption ionization time-of-flight mass spectrometry, accelerates pathogen identification and enables earlier appropriate therapy modification. Studies demonstrate that coupling rapid diagnostics with real-time stewardship interventions reduces time to optimal therapy by twelve to thirty-six hours compared to conventional culture-based methods, translating into shorter hospital stays and decreased mortality in patients with bloodstream infections. Resistance trends show stabilization or modest reduction in facilities implementing comprehensive antimicrobial stewardship programs over sustained periods. While individual institutional efforts alone cannot reverse global resistance trends driven by agricultural antimicrobial use and international transmission, healthcare facilities serving as stewardship exemplars demonstrate that coordinated interventions can meaningfully impact local resistance epidemiology. These successes provide proof of concept that broader implementation could achieve substantial population-level benefits.

Discussion

The evidence base supporting antimicrobial stewardship has matured substantially, transitioning from theoretical frameworks to robust documentation of clinical and economic benefits. Systematic reviews and meta-analyses consistently demonstrate that comprehensive stewardship programs reduce inappropriate antimicrobial use without compromising patient safety, addressing historical concerns that restrictive policies might delay necessary therapy or increase adverse outcomes. The key appears to be implementing stewardship as a supportive rather than purely restrictive endeavor, emphasizing education, decision support, and collaborative engagement rather than punitive oversight. Comparison of different stewardship intervention strategies reveals that multimodal approaches incorporating both restrictive elements and prospective audit with feedback achieve superior results compared to single-component interventions. Formulary restrictions alone may reduce use of specific agents but risk squeezing the balloon, shifting prescribing to alternative broad-spectrum agents rather than promoting appropriate narrow-spectrum therapy. Prospective audit with feedback allows nuanced case-by-case evaluation and provides valuable educational opportunities, though resource requirements may limit feasibility in smaller facilities. The optimal approach likely involves combining formulary optimization with active stewardship review for high-risk antimicrobials, supported by institution-specific guidelines and prescriber education.

Pharmacokinetic-pharmacodynamic optimization is underused for maximizing antimicrobial efficacy and limiting resistance, especially in critically ill patients with altered drug handling. Therapeutic drug monitoring, extended infusions, and dose adjustments can improve outcomes but are inconsistently applied. Stewardship barriers include limited resources, prescriber reluctance, and insufficient organizational support. Future threats involve new resistance mechanisms, environmental gene spread, and slow antimicrobial development. Expanded stewardship across hospitals, outpatient care, long-term facilities, and veterinary settings is essential to curb resistance effectively.

Antimicrobial resistance threatens modern medicine, affecting infection treatment, surgery, and transplantation. Effective stewardship-including empirical selection, de-escalation, pharmacokinetic-

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

pharmacodynamic optimization, and prudent combination therapy-is essential. Coordinated action across healthcare, agriculture, and public health is critical to preserve antimicrobial efficacy for current and future patients.

References

1. Pattoyevich, G. A., & Nilufar, M. (2025, June). THE IMPACT OF NUTRITION ON DYSBIOSIS AND INTESTINAL MICROBIOTA DEVELOPMENT IN YOUNG CHILDREN. In Scientific Conference on Multidisciplinary Studies (pp. 188-194).
2. Хасанбоева, Н. А. (2021). ЦЕЛЕБНЫЕ СВОЙСТВА ПРЕПАРАТОВ, ПОЛУЧЕННЫЕ ИЗ ПРОДУКТА ХВОИ. Интернаука, 22, 76.
3. Abdullajonovna, H. N. INTERACTION BETWEEN DRUG SUBSTANCES AND NUTRIENT PRODUCTS. International Journal of Advanced Research in ISSN, 2278-6252.
4. Abdullajonovna, N. X. (2025, February). ADVERSE EFFECTS OF SALICYLATES. In International Educators Conference (pp. 119-125).
5. Aliyevna, P. L. Z., & Ibroxim o'g, G. A. H. (2023). OBESITY-CAUSES, PREVALENCE, CLINICS, DIAGNOSIS AND TREATMENT MEASURES. INTERNATIONAL JOURNAL OF ADVANCED RESEARCH IN EDUCATION, TECHNOLOGY AND MANAGEMENT, 2(10).
6. Aliyevna, P. Z. (2025). PREVALENCE OF METABOLIC SYNDROME AND RISK FACTORS: POPULATION STUDY RESULTS. GLOBAL TRENDS IN SCIENCE AND INNOVATION, 1(1), 168-169.
7. Aliyevna, P. Z. (2025). DEVELOPMENT OF AN INTEGRAL RISK INDEX FOR METABOLIC SYNDROME. GLOBAL TRENDS IN SCIENCE AND INNOVATION, 1(1), 166-167.
8. Тешаев, Ш. Ж., & Пулатова, З. А. (2023). ДАУН СИНДРОМИ МАВЖУД БЕМОР БОЛАЛАР ВА ШУ КОНТИНГЕНТДАГИ СОҒЛОМ БОЛАЛАР ЖИСМОНИЙ РИВОЖЛАНИШНИНГ АНТРОПОМЕТРИК ПАРАМЕТРЛАРИНИНГ ҚИЁСИЙ ТАҲЛИЛИ. Журнал гуманитарных и естественных наук, (4 [2]), 30-35.
9. Teshaev, S. J., & Pulatova, Z. A. (2023). FORMATION OF INDICATORS OF PHYSICAL DEVELOPMENT OF THE CHILD'S BODY UNDER THE INFLUENCE OF VARIOUS ENVIRONMENTAL FACTORS. Журнал гуманитарных и естественных наук, (3 [2]), 21-26.
10. Sheraliyevich, A. B. (2025, February). LASER HAIR REMOVAL: DIODE LASER. In International Conference on Modern Science and Scientific Studies (pp. 8-11).
11. Sheraliyevich, A. B. (2025). LASERS FOR ACNE, COMBINATIONS OF LASERS AND LIGHTS WITH MEDICAL THERAPIES. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(2), 422-425.
12. Исакёнович, С.М. (2025). ЭФИРНЫЕ МАСЛА И ИХ АНТИМИКРОБНОЕ ДЕЙСТВИЕ. Web of Medicine: Журнал медицины, практики и сестринского дела , 3 (5), 654-660.
13. Isakjonovich, S. M. (2024). THE EFFECT OF MEDICINAL PLANTS ON THE INFLAMMATORY PROCESS. Ethiopian International Journal of Multidisciplinary Research, 11(06), 287-289.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

14. Саримсаков, М. М., & Султанова, Р. Х. ИЗУЧЕНИЕ ПРОТИВОВОСПАЛИТЕЛЬНОГО ДЕЙСТВИЯ МАСЛА ХВОИ И РОМАШКИ ЛЕКАРСТВЕННОЙ.
15. Kamalovich, S. I. (2025). ORGAN-PRESERVING SURGICAL TECHNIQUES AND PROGNOSIS IN PEDIATRIC PATIENTS WITH HEPATIC AND TUMOR PATHOLOGIES. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 693-700.
16. Kamalovich, S. I., & Isroilovna, S. M. (2025, June). THE ROLE OF LAPAROSCOPY IN THE MANAGEMENT OF PEDIATRIC APPENDICITIS. In Scientific Conference on Multidisciplinary Studies (pp. 269-274).
17. Sharapov, I. K. (2024). CONGENITAL ESOPHAGEAL DEFECTS IN CHILDREN. Analysis of world scientific views International Scientific Journal, 2(1), 107-112.
18. Kamalovich, S. I. (2022). Modern Methods of Surgical Treatment of Gastric Ulcer and Duodenal Ulcer. Texas Journal of Medical Science, 15, 91-95.
19. Kamalovich, S. I. (2023). Congenital Esophageal Defects in Children. Research Journal of Trauma and Disability Studies, 2(12), 180-184.
20. Khodjiakbarovna, K. M. (2025, February). THE ROLE OF THERAPEUTIC PHYSICAL EXERCISES IN COVID-19 RECOVERY. In International Conference on Modern Science and Scientific Studies (pp. 3-7).
21. Khodjiakbarovna, K. M. (2025, February). NEGATIVE CONSEQUENCES OF HELMINTH INFECTIONS AND PREVENTIVE MEASURES IN TREATMENT. In International Conference on Modern Science and Scientific Studies (pp. 323-326).
22. Мурадимова, А. Р., & Ахмедова, Ф. Ш. (2019). Сестринский уход за пациентами при геморрагическом инсульте. In Инновации в медицине. Материалы I международной научно-практической конференции-Махачкала, 2019.-Том. II.-232 с. (p. 188).
23. Shakhzodakhon, S. (2025, June). OCCUPATIONAL ALLERGIES: RISK FACTORS, DIAGNOSIS, AND DEVELOPMENT OF PREVENTIVE MEASURES. In Scientific Conference on Multidisciplinary Studies (pp. 275-281).
24. Solijon o‘g‘li, A. S. (2025). Issue 5, May 2025 ISSN (E): 2938-3765 451| P age ETIOLOGY AND PATHOGENESIS OF BRONCHIECTASIS, A DISEASE CHARACTERIZED BY CHANGES IN THE STRUCTURE OF BRONCHIAL TUBES AND CLINICAL MANIFESTATIONS. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 451-458.
25. Абдуллаев, С. (2025). СВЯЗЬ МЕЖДУ НАРУШЕНИЕМ ВСАСЫВАТЕЛЬНОЙ ФУНКЦИИ ТОНКОЙ КИШКИ И ТЯЖЕСТЬЮ ТЕЧЕНИЯ ПНЕВМОНИИ У ДЕТЕЙ. Модели и методы в современной науке, 4(7), 147-151.
26. Anvarovna, A. I., & PNEUMONIA, I. 1-YEAR-OLD CHILDREN: SYMPTOMS, TREATMENT AND PREVENTION. SCIENTIFIC JOURNAL OF RESEARCH IN MEDICINE (SJRM) Vol, 1, 9-12.
27. Алимова, И. А., & Марасулова, М. (2024). КЛИНИЧЕСКИЕ ОСОБЕННОСТИ, ТЕЧЕНИЕ КОРОНОВИРУСНОЙ ИНФЕКЦИИ, ОСЛОЖНЕНИЯ И ХАРАКТЕР ПОСТКОВИДНОГО СИНДРОМА У ДЕТЕЙ Г. ФЕРГАНЫ. INNOVATIVE DEVELOPMENTS AND RESEARCH IN EDUCATION, 3(30), 276-283.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

28. Anvarova, Z. (2025). TIBBIY O ‘QUV MATERIALINI MUSTAQIL O ‘ZLASHTIRISHDA TALABALARNING KLINIK AUDIT KO ‘NIKMALARNI RIVOJLANTIRISH METODIKASI. Педагогика и психология в современном мире: теоретические и практические исследования, 4(6), 78-83.
29. Farinoz, A. (2025, January). EXTERNAL OTITIS IN CHILDREN AND ITS TREATMENT. In International Conference on Multidisciplinary Sciences and Educational Practices (pp. 48-55).
30. Muxammadrasul, M. (2024, May). Etiology and Pathophysiology of Diabetes Mellitus. In International Congress on Biological, Physical And Chemical Studies (ITALY) (pp. 92-96).
31. Саиджалилова, Д. Д., & Ғуломова, Р. И. (2023). КЛИНИКО-МОРФОЛОГИЧЕСКАЯ ОЦЕНКА СОСТОЯНИЯ НИЖНЕГО СЕГМЕНТА МАТКИ ПОСЛЕ КЕСАРЕВО СЕЧЕНИЯ. ЖКМП, 4(4).
32. Гуломова, Р. И., & Алижонова, Ш. Т. (2022). Особенности операции кесарева сечения на современном этапе. Мировая наука, (6 (63)), 66-69.
33. Umarovich, B. M. (2025, June). PATHOGENESIS, IMMUNITY, PATHOLOGY AND CLINICAL MANIFESTATIONS OF MEASLES. In Scientific Conference on Multidisciplinary Studies (pp. 303-309)

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5